PharmAust is a clinical-stage company developing novel targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development.
Monepantel trial achieves successful anti-cancer outcome - Recruitment on hold during interim analysis and report preparation.
PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, which is a highly successful contract medicinal chemistry company that generates significant annual revenues.